Shots:

• The P-III COMBI-AD trial involves assessing of Tafinlar (150mg bid) + Mekinist (2mg qd) vs PBO in 438 patients with BRAF V600-mutant stage III Melanoma for 44 months and 42 months respectively
• During the extended follow-up cure rate was 54% vs 37%
• P-III COMBI-AD trial results: RFS rate @ 44 &42 mos. (59%- 54% vs 40%- 38%); patients with no relapse (54% vs 37%); risk of disease recurrence or death by 53%. RFS@ 1- 2- 3- 4yrs.- (88%- 67%- 59%- 54% vs 56%- 44%- 40%- 38%) respectively
• Tafinlar + Mekinist used for targeting multiple kinases in serine/threonine kinase family-BRAF & MEK1/2 and the combination is currently approved in 60 countries 

/ article | Ref: Novartis | Image: Financial Times